The diagnosed prevalent cases of non-alcoholic steatohepatitis (NASH/MASH) in the seven major markets (7MM*) are projected to increase from 22.04 million in 2022 to 26.55 million in 2032, registering an annual growth rate (AGR) of 2.05%, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report: ‘Non-Alcoholic Steatohepatitis (NASH/MASH): Epidemiology Forecast to 2032’ estimates that in 2032, the US will have the highest number of diagnosed prevalent cases of NASH in the 7MM, with 10.45 million cases, whereas Spain will have the fewest diagnosed prevalent cases, with 1.15 million cases. In the 5EU**, GlobalData estimates there will be 11.77 million diagnosed prevalent cases of NASH in 2032.

Casey Freimuth, Senior Epidemiologist at GlobalData, comments: “Best practices to predict the future burden of NASH will be to observe trends in NAFLD and risk factors like obesity and type 2 diabetes. Surveillance of other risk factors such as waist circumference, body mass index, triglycerides, and gamma-glutamyl Transferase levels, will be crucial to understanding the risk of NAFLD, and therefore the risk of NASH, in a population.”

In the 7MM, between 12% and 20% of diagnosed prevalent cases of NASH present with stage 4 liver fibrosis. Stage 4 indicates severe liver damage due to cirrhosis. There is no treatment to cure cirrhosis so early diagnosis of NASH is crucial. Effective management of the underlying causes of non-alcholic cirrhosis such as obesity and insulin resistance can prevent liver failure.

*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan

**5EU: France, Germany, Italy, Spain, and the UK